STOCK TITAN

MiNK Therapeutics (INKT) Financials

INKT NASDAQ
Trailing 12 months to September 30, 2026
Revenue Not reported for the trailing 12 months
Net Income -$11.0M n/m YoY
EPS (Diluted) -$2.23 n/m YoY
Operating Cash Flow -$7.2M n/m YoY
Market Cap $47.7M as of Nov 17, 2026
Price / Sales n/m no full year of revenue reported yet
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 30, 2026
Price / Book n/m negative shareholder equity, so no book multiple, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 30, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 12, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the INKT SEC filings page.

This page shows MiNK Therapeutics, Inc. (INKT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI INKT FY2025

External financing remains central to the business, while persistent losses leave liabilities above assets despite better near-term liquidity.

The financing pattern is more revealing than the narrower loss: FY2025 operating cash flow was -$5.9M while financing cash flow supplied $14.7M, so operations still depended on new capital rather than self-funding. At the same time, liabilities were 199.9% of assets, meaning the improved 1.1x current ratio reflects short-term coverage—not a balance sheet restored to positive equity.

Spending has been reconfigured rather than simply scaled back: R&D fell 62.8% from FY2023 to FY2025, while SG&A fell 9.4% over the same span. That mix shift coincided with a FY2025 operating loss of $12.6M, so lower research spending has not yet made the operation profitable.

FY2025 assets stood at $14.2M while liabilities reached $28.5M. That left equity negative at $14.2M; the 1.1x current ratio improved from 0.7x in FY2024, but this measures short-term asset coverage and does not erase the longer-term deficit.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Financial health score not available

We do not publish a peer-relative financial health score for MiNK Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.

Piotroski F-Score Partial
3/6

MiNK Therapeutics, Inc. passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.

Earnings Quality No Cash Backing
N/A

MiNK Therapeutics, Inc. reported a net loss of $12.5M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

MiNK Therapeutics, Inc. reported an operating loss of $12.6M against $110K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$200K
YoYn/m

MiNK Therapeutics, Inc. generated $200K in revenue in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.

EBITDA
-$2.6M
YoYn/m
QoQn/m

MiNK Therapeutics, Inc.'s EBITDA was -$2.6M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income
-$2.6M
YoYn/m
QoQn/m
5Y CAGRn/m

MiNK Therapeutics, Inc. reported a net loss of $2.6M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.50
YoYn/m
QoQn/m

MiNK Therapeutics, Inc. earned -$0.50 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Cash & Debt
$7.5M
YoY-21.4%
QoQ-15.2%
5Y CAGR+55.6%

MiNK Therapeutics, Inc. held $7.5M in cash as of Q3 2026; no long-term debt figure is on record for that period.

Shares Outstanding
5M
YoY+9.4%
QoQ+0.6%

MiNK Therapeutics, Inc. had 5M shares outstanding in Q3 2026. This represents an increase of 9.4% from the same quarter a year earlier. Against the prior quarter it is up 0.6%.

Free Cash Flow

Not reported for Q3 2026.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin

Not reported for Q3 2026.

Operating Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q3 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q3 2026.

Capital Allocation

R&D Spending
$1.8M
YoY+57.8%
QoQ-4.4%
5Y CAGR-11.6%

MiNK Therapeutics, Inc. invested $1.8M in research and development in Q3 2026. This represents an increase of 57.8% from the same quarter a year earlier. Against the prior quarter it is down 4.4%.

Share Buybacks

Not reported for Q3 2026.

Capital Expenditures

Not reported for Q3 2026.

INKT Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INKT quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$200Kn/mN/AN/AN/A$0N/AN/AN/A
R&D Expenses$1.8M+57.8%$1.9M+2.6%$1.2M-4.6%$1.5M+7.6%$1.1M+111.4%$1.8M0.0%$1.3M-50.5%$1.4M-57.5%
SG&A Expenses$1.0M-44.0%$1.3M-28.1%$1.7M+32.0%$1.8M+118.0%$1.8M+58.8%$1.8M+74.2%$1.3M-0.7%$809K-63.1%
Operating Income-$2.6Mn/m-$3.2Mn/m-$2.9Mn/m-$2.7Mn/m-$3.2Mn/m-$4.1Mn/m-$2.7Mn/m-$2.5M
EBITDA-$2.6Mn/m-$3.2Mn/m-$2.8Mn/mN/A-$3.1Mn/m-$4.0Mn/m-$2.6Mn/mN/A
Interest Expense-$1Kn/m-$2Kn/m-$4Kn/mN/A-$25Kn/m-$27Kn/m-$29Kn/mN/A
Net Income-$2.6Mn/m-$3.1Mn/m-$2.7Mn/m-$2.6Mn/m-$2.9Mn/m-$4.2Mn/m-$2.8Mn/m-$2.5Mn/m
EPS (Basic)-$0.50n/m-$0.62n/m-$0.57n/m-$0.54n/m-$0.65n/m-$1.06n/m-$0.70n/m-$0.62n/m
EPS (Diluted)-$0.50n/m-$0.62n/m-$0.57n/m-$0.54n/m-$0.65n/m-$1.06n/m-$0.70n/m-$0.62n/m
Diluted Shares (Avg)5M+14.8%5M+26.2%5M+21.0%N/A4M+12.4%4M+7.2%4M+14.5%N/A

Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Income Tax.

INKT Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INKT quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'25FilingQ4'2410-K
Total Assets$8.2M-44.9%$9.6M+287.0%$10.4M+143.2%$14.2M+148.9%$15.0M+102.9%$2.5M-75.9%$4.3M-38.1%$5.7M+25.7%
Current Assets$7.9M-45.6%$9.3M+362.2%$10.0M+180.0%$13.8M+177.6%$14.5M+121.0%$2.0M-78.8%$3.6M-40.3%$5.0M+38.6%
Cash & Equivalents$7.5M-21.4%$8.8M+423.6%$9.5M+194.5%$13.4M+191.9%$9.5M+50.1%$1.7M-81.9%$3.2M-44.4%$4.6M+35.9%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m
Total Liabilities$24.5M-14.0%$23.6M-14.6%$23.1M-11.5%$28.5M+12.5%$28.5M+14.2%$27.7M+2.9%$26.1M-4.2%$25.3M+11.9%
Current Liabilities$8.2M-39.1%$7.6M-42.5%$7.3M-39.9%$13.0M+87.2%$13.4M+81.6%$13.2M+29.7%$12.1M+9.1%$7.0M-39.0%
Non-Current Liabilities$16.3M+8.5%$16.1M+10.8%$15.8M+13.2%$15.4M-15.9%$15.0M-14.2%$14.5M-13.4%$13.9M-13.3%$18.3M+63.7%
Total Equity-$16.3Mn/m-$14.0Mn/m-$12.7Mn/m-$14.2Mn/m-$13.5Mn/m-$25.2Mn/m-$21.8Mn/m-$19.6Mn/m
Retained Earnings-$165.1Mn/m-$162.5Mn/m-$159.4Mn/m-$156.7Mn/m-$154.1Mn/m-$151.2Mn/m-$146.9Mn/m-$144.2Mn/m

Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.

INKT Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INKT quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow-$1.3Mn/m-$2.1Mn/m-$1.7Mn/m-$2.1Mn/m-$941Kn/m-$1.6Mn/m-$1.3Mn/m-$1.7Mn/m
Depreciation & Amortization$36K-17.4%$36K-26.0%$36K-29.0%$39K-28.4%$44K-30.3%$49K+8.1%$51K-5.7%$54K+0.6%
Stock-Based Compensation$333K-46.4%$422K-53.0%$630K+6.6%N/A$621K-29.7%$897K+6.3%$591K-0.2%N/A
Financing Cash Flow$0-100.0%$1.4M+252891.5%-$2.1M-364827.4%$1.2Mn/m$13.5M+198954.8%$540-100.0%$576-100.0%-$3n/m

Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Investing Cash Flow, Dividends Paid, Share Buybacks.

INKT Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

INKT quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Margin-1318.6%N/AN/AN/AN/AN/AN/AN/A
Net Margin-1276.1%N/AN/AN/AN/AN/AN/AN/A
Return on Assets-31.0%-11.7pp-32.5%+138.0pp-26.4%+38.4pp-18.3%+24.8pp-19.3%+5.2pp-170.6%-144.4pp-64.8%-9.5pp-43.1%+76.9pp
Current Ratio0.97-0.1x1.23+1.1x1.38+1.1x1.06+0.3x1.08+0.2x0.15-0.8x0.30-0.2x0.72+0.4x
Asset Turnover0.020.0xN/AN/AN/A0.00N/AN/AN/A

Not reported in any period shown, so not listed: Gross Margin, Return on Equity, Debt-to-Equity, Liabilities-to-Equity, FCF Margin.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Note: Shareholder equity is negative (-$14.2M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
MiNK Therapeutics, Inc. INKT FY2025 N/A -$12.5M N/A $47.7M —
Werewolf Therapeutics, Inc. HOWL FY2025 N/A -$60.8M N/A $51.0M —
Pliant Therapeutics, Inc. PLRX FY2025 $0 -$149.3M N/A $40.9M —
Oncolytics Biotech, Inc. ONCY FY2025 N/A -$28.8M N/A $52.1M —
Rein Therapeutics, Inc. RNTX FY2025 $0 -$49.9M N/A $30.7M —
Gain Therapeutics, Inc. GANX FY2025 N/A -$20.2M N/A $52.5M —

Frequently Asked Questions

No, MiNK Therapeutics, Inc. (INKT) reported a net loss of $11.0M over the trailing 12 months to September 30, 2026. In fiscal year 2025 it reported a net loss of $12.5M.

MiNK Therapeutics, Inc. (INKT) reported diluted earnings per share of -$2.93 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

MiNK Therapeutics, Inc. (INKT) had EBITDA of -$12.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

MiNK Therapeutics, Inc. (INKT) recorded an outflow of $5.9M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

MiNK Therapeutics, Inc. (INKT) had $14.2M in total assets as of fiscal year 2025, including both current and long-term assets.

MiNK Therapeutics, Inc. (INKT) invested $5.8M in research and development during fiscal year 2025.

MiNK Therapeutics, Inc. (INKT) had 5M shares outstanding as of fiscal year 2025.

MiNK Therapeutics, Inc. (INKT) had a current ratio of 1.06 as of fiscal year 2025, which is considered adequate.

MiNK Therapeutics, Inc. (INKT) had a return on assets of -87.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

MiNK Therapeutics, Inc. (INKT) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 30, 2026). The market capitalization is $47.7M as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

MiNK Therapeutics, Inc. (INKT) has no price-to-sales ratio at the moment: no full year of revenue reported yet. The market capitalization is $47.7M as of Nov 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

At the end of fiscal year 2025, MiNK Therapeutics, Inc. (INKT) held $13.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $5.9M over that year. Dividing the one by the other, the reported balance equals about 27 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

MiNK Therapeutics, Inc. (INKT) has negative shareholder equity of -$14.2M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

MiNK Therapeutics, Inc. (INKT) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

MiNK Therapeutics, Inc. (INKT) reported a net loss of $12.5M while operations used $5.9M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

MiNK Therapeutics, Inc. (INKT) reported an operating loss of $12.6M against $110K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

Back to top